Cocrystal Pharma, Inc.
Tucker, Georgia, United States · Biotechnology, Healthcare, Health Care
Cocrystal (OTCQB:COCP) is a pharmaceutical company.
Key facts
- Headquarters
- Tucker, Georgia, United States
- Employees
- 11
- Industries
- Biotechnology, Healthcare, Health Care
- Status
- Public (COCP)
- Website
- cocrystalpharma.com
Recent activity at Cocrystal Pharma, Inc.
- : SEC 8-K (7.01): On September 9, 2026, Cocrystal Pharma, Inc. announced through a press release that the last subject has been dosed in its Phase 1b norovirus challenge study (NCT07198139). This study evaluates the efficacy of CDI-988 as both a preventive and treatment option for norovirus infections. The completion of this dosing marks a significant milestone in the clinical development of the drug, which aims to address a significant public health challenge associated with norovirus. The press release is included as Exhibit 99.1 in the filing.
- : Cocrystal Pharma Appoints James Sapirstein as Chief Executive Officer
- : SEC 8-K (7.01): On March 9, 2026, Cocrystal Pharma, Inc. issued a press release regarding the progress of their Phase 1b norovirus challenge study evaluating CDI-988 as both a preventive and therapeutic option for norovirus infections. This update provides significant information for investors, highlighting the ongoing research efforts and signaling the company's commitment to addressing health challenges posed by norovirus. The timing of this disclosure is crucial as it aligns with their research development timeline, which can impact stock performance and investor interest.
- : SEC 8-K (1.01): On October 28, 2025, Cocrystal Pharma, Inc. entered into a Securities Purchase Agreement with four accredited investors, referred to as the Purchasers, allowing them to purchase 739,426 units of the Company's securities at a price of $1.39 per unit. Each unit consists of one share of common stock and one warrant for two additional shares at $1.24 per share, exercisable over 27 months. This transaction generated gross proceeds of $1.03 million and involved four insiders of the Company, indicating potential strategic implications for insider confidence in Cocrystal's future. Notably, the Purchasers did not receive registration rights for their purchase, which may affect liquidity for the shares in the near term.
- : Cocrystal Pharma, Inc.
- : Cocrystal Pharma, Inc.
- : Cocrystal Pharma, Inc.
Cocrystal Pharma, Inc. funding history
| Date | Round | Amount |
|---|---|---|
| May 2017 | Seed | $3.0M |
| Sep 2016 | Seed | $4.0M |
| Mar 2016 | Venture | $5.0M |
Leadership
- Gary Wilcox, Vice Chairman of the Board of Directors
- Raymond Schinazi, Director
- Steven Rubin, Director
- Jane Hsiao, Director
- Phillip Frost, Director
- David Block, Director
- Gary Wilcox, Executive Officer, Director
- Raymond Schinazi, Director
- Steven Rubin, Director
- Jane Hsiao, Director
- Phillip Frost, Director
- David Block, Director
Verified email and direct lines for Cocrystal Pharma, Inc.’s decision-makers are on Fundz. See plans
Employee benefit plans
Cocrystal Pharma, Inc. files 2 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.
Cocrystal Pharma, Inc. in the news
- Cocrystal Pharma Receives FDA Fast Track Designation for CDI-988 for Norovirus Infection Treatment and Preventive - GlobeNewswire (Apr 02, 2026)
- Cocrystal Pharma Announces Discovery of Pan-Viral Inhibitors Targeting Hantavirus, Bunyavirus and Influenza - Yahoo Finance (May 26, 2026)
- Cocrystal Pharma, Inc. (COCP) stock price, news, quote and history - Yahoo Finance UK (May 18, 2017)
Companies similar to Cocrystal Pharma, Inc.
- Aarvik Therapeutics · Biotechnology, Healthcare, Health Care, Therapeutics
- GALECTIN THERAPEUTICS INC · Biotechnology, Healthcare, Health Care, Therapeutics
- Os Therapies · Biotechnology, Healthcare, Health Care, Therapeutics
- Adial Pharmaceuticals · Biotechnology, Healthcare, Health Care, Therapeutics
- Phio Pharmaceuticals · Biotechnology, Healthcare, Health Care, Therapeutics
About Cocrystal Pharma, Inc.: questions and answers
What does Cocrystal Pharma, Inc. do?
Cocrystal (OTCQB:COCP) is a pharmaceutical company.
Where is Cocrystal Pharma, Inc. headquartered?
Cocrystal Pharma, Inc. is headquartered in Tucker, Georgia, United States.
How many employees does Cocrystal Pharma, Inc. have?
Cocrystal Pharma, Inc. has about 11 employees.
Has Cocrystal Pharma, Inc. raised funding?
Yes. Fundz has recorded 3 funding events for Cocrystal Pharma, Inc.. The most recent, Seed of $3.0M, was in May 2017.
What is the latest news on Cocrystal Pharma, Inc.?
On Sep 09, 2026, SEC 8-K (7.01): On September 9, 2026, Cocrystal Pharma, Inc. announced through a press release that the last subject has been dosed in its Phase 1b norovirus challenge study (NCT07198139). This study evaluates the efficacy of CDI-988 as both a preventive and treatment option for norovirus infections
Is Cocrystal Pharma, Inc. a public company?
Yes. Cocrystal Pharma, Inc. is publicly traded under the ticker COCP.
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy